Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Immucell (ICCC) Other Operating Expenses (2016 - 2025)

Immucell (ICCC) has disclosed Other Operating Expenses for 16 consecutive years, with -$62319.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Other Operating Expenses changed N/A year-over-year to -$62319.0, compared with a TTM value of $776091.0 through Sep 2025, down 1.31%, and an annual FY2024 reading of $3.5 million, up 42896.3% over the prior year.
  • Other Operating Expenses was -$62319.0 for Q3 2025 at Immucell, down from $7128.0 in the prior quarter.
  • Across five years, Other Operating Expenses topped out at $992556.0 in Q4 2022 and bottomed at -$396629.0 in Q2 2022.
  • Average Other Operating Expenses over 5 years is $380475.6, with a median of $436982.0 recorded in 2021.
  • Peak annual rise in Other Operating Expenses hit 9816.4% in 2024, while the deepest fall reached 19253.95% in 2024.
  • Year by year, Other Operating Expenses stood at $889929.0 in 2021, then rose by 11.53% to $992556.0 in 2022, then plummeted by 70.36% to $294217.0 in 2023, then soared by 184.19% to $836147.0 in 2024, then plummeted by 107.45% to -$62319.0 in 2025.
  • Business Quant data shows Other Operating Expenses for ICCC at -$62319.0 in Q3 2025, $7128.0 in Q2 2025, and -$4865.0 in Q1 2025.